Invivyd (IVVD) is a clinical-stage biotech, ≈$0.4B market cap, $1.21/share at filing date. One commercial product (PEMGARDA, COVID mAb prophylaxis under EUA) and one binary catalyst (VYD2311 DECLARATION Phase 3, top-line Q3 2026). The 10-Q filed 2026-05-14 leaves the binary structure unchanged but adds three datapoints worth pricing.

What the filing says

DECLARATION underwent a halfway-point sample-size re-estimation. The trial moved from 1,818 to ≈2,318 subjects. Management framing: "clinical events accrued to date could support statistical powering for the high end of anticipated VYD2311 efficacy levels." SSRE algorithms operate on blinded data. The trigger criterion under their adaptive design implies events at the halfway readout already support best-case powering — not insufficient accrual.

Going concern reiterated, SVB facility undrawn. $184.2M cash at March 31 2026, plus $19.4M April ATM (11.8M shares at $1.70). Q1 burn $42.5M/quarter — runway extends into Q1-Q2 2027, past the Q3 2026 readout. The SVB $30M term loan is inaccessible because product revenue milestones haven't been met. PEMGARDA Q1 revenue was $13.7M, +22% YoY, 92.5% gross margin.

Three WuXi Biologics agreements amended March 4, 2026 — commercial manufacturing extended to 2036, cell line license, and clinical MSA. A "Termination Due to Legal Reasons" clause was added covering US government contract eligibility. BIOSECURE Act (Section 851 NDAA FY26) was enacted Dec 18, 2025; the 2036 extension exceeds the 5-year pre-enactment safe harbor.

CFO serves as Principal Executive Officer. No CEO. 2026 Inducement Plan (8M shares, January 2026) signals active search.

What the market thinks

Stock at $1.21, down 29% over the trailing month. Three covering analysts, all at Buy, $10 mean price target. Naive arithmetic from current price to mean target implies P(trial hit) of roughly 12-15%. April ATM was 23.5M shares at a 29% discount to recent trading. Going concern, dilution capitulation, no CEO — the price reflects a structurally distressed binary.

Why the gap exists

Historical base rate on the COVID mAb Phase 3 statistical primary endpoint is ≈100% in the cleared trials: COMET-ICE (sotrovimab, stopped early for efficacy), PROVENT, TACKLE (Evusheld), BLAZE-1 (bamlanivimab), REGEN-COV 2069, and CANOPY (pemivibart itself). The dominant failure mode for the class is variant escape, not statistical underpowering. VYD2311 was confirmed neutralizing against BA.3.2.2 ("Cicada"), the current circulating strain, as of May 2026 — disconfirming the dominant failure mode within the readout window.

The structural reason the market underweights this: at $0.4B market cap with a going-concern disclosure, no index funds hold the name and institutional desks can't size meaningfully into a single binary with -90% tail risk. The price clears at marginal forced-seller terms — dilution capitulation, retail, and tax-loss. Three analyst Buys at $10 confirm the direction is consensus; the spot price reflects sizing constraints, not analytical disagreement on outcome.

Filing-derived P(statistical hit) ≈ 0.65-0.75. Market-implied ≈ 0.15-0.20. The gap is in magnitude, not sign.

Risks (ranked)

1. Variant escape between now and Q3 2026. BA.3.2.2 is covered; successor strains may not be. The single empirical disconfirmation has a 4-month half-life.
2. Statistical miss on primary endpoint. Base rate ≈100% historically but n=6, not n=60. Each new trial is a fresh draw.
3. FDA finds non-statistical deficiency post-hit. CMC, manufacturing, label — would compress the positive scenario without flipping it.
4. Pre-data dilution. $350M shelf + $75M ATM remaining. A pre-data raise at distressed levels caps upside on hit.
5. CEO vacuum during binary. Manageable but unusual; complicates post-data communications.
6. BIOSECURE / WuXi tail. Multi-year, hedged by termination clause but not eliminated.

Catalysts

• May-Sep 2026: Possible CEO hire 8-K, possible DSMB-triggered events (silent unless stopped)
• Aug 2026: Q2 2026 10-Q with PEMGARDA print
• Q3 2026: DECLARATION top-line — the event
• Q4 2026: BLA filing (conditional on hit)
• H1 2027: FDA decision (conditional on filing)

What would change our mind

• Variant breakthrough disclosure that VYD2311 does not neutralize → core thesis broken
• 8-K disclosing trial halt for safety or futility → exit
• Auditor resignation or fraud allegation → exit
• Insider Form 4 S-codes (open-market sales, not vest-and-sell) within readout window → significant downgrade
• BLA filing delay disclosed post-data → compresses positive scenario

The trade is a directional bet on a dated catalyst where the dominant failure mode has been empirically disconfirmed within the readout window. The market and the analyst panel agree on direction; spot price reflects who can hold it, not what's likely.

Evidence